Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ELU 001

Drug Profile

ELU 001

Alternative Names: ELU-001

Latest Information Update: 20 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Elucida Oncology
  • Class Alkaloids; Antineoplastics; Camptothecins; Drug conjugates; Folic acids; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Preclinical Acute myeloid leukaemia; Ovarian cancer

Most Recent Events

  • 08 Dec 2023 Elucida Oncology withdraws a phase I trial for Acute myeloid leukemia (In children, In infants, Second-line therapy or greater) prior to enrollment (IV,Infusion) (NCT05622591)
  • 24 Oct 2023 Adverse events data from a phase I/II trial in Solid tumours released by Elucida Oncology
  • 20 Oct 2023 Adverse event data from a phase I/II trial in Solid tumours presented at 48th European Society for Medical Oncology Congress (ESMO-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top